Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8530172 | 0.87 | POLB (0.53) | SIRT1POLBKDM4EALDH1A1TDP1 | |
| SCHEMBL231042 | 0.82 | SIRT1 (0.71) | MEN1MAPTHPGDKMT2ASIRT1 | |
| SCHEMBL6934354 | 0.82 | SIRT1 (0.53) | MAPTSIRT1POLBKDM4EALDH1A1 | |
| SCHEMBL1447741 | 0.82 | KDM4E (0.59) | MAPTHPGDSIRT1POLBKDM4E | |
| SCHEMBL6556789 | 0.82 | MEN1 (0.46) | MEN1GAAMAPTHPGDKMT2A | |
| SCHEMBL6781026 | 0.81 | NPC1 (0.56) | MEN1KMT2ASIRT1SLC6A9POLB | |
| SCHEMBL29269633 | 0.81 | MEN1 (0.51) | MEN1GAAMAPTHPGDKMT2A | |
| SCHEMBL30402483 | 0.81 | MEN1 (0.51) | MEN1GAAMAPTHPGDKMT2A | |
| SCHEMBL11013368 | 0.81 | SIRT1 (0.51) | MEN1MAPTKMT2ASIRT1POLB | |
| SCHEMBL8530243 | 0.81 | MEN1 (0.53) | MEN1MAPTKMT2ASIRT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035268-A2 | TAU PATHWAY MODULATORS | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2024-02-15 | — | — | WO | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| EP-1197491-B1 | Thioxanthenone antitumor agents | SANOFI AVENTIS (FR) | 2004-12-29 | — | — | EP | disclosed |
| EP-0917458-B1 | LYOPHILIZED THIOXANTHENONE ANTIMUMOR AGENTS | SANOFI SYNTHELABO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0882723-B1 | Thioxanthenone antitumor agents | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| EP-1197491-A1 | Thioxanthenone antitumor agents | SANOFI-SYNTHELABO (FR) | 2002-04-17 | — | — | EP | disclosed |
| EP-0619315-B1 | Thioxanthenone antitumor agents | SANOFI SA (FR) | 1999-06-09 | — | — | EP | disclosed |
| EP-0917458-A1 | LYOPHILIZED THIOXANTHENONE ANTIMUMOR AGENTS | SANOFI (FR) | 1999-05-26 | — | — | EP | disclosed |
| EP-0882723-A1 | Thioxanthenone antitumor agents | SANOFI (FR) | 1998-12-09 | — | — | EP | disclosed |
| US-5665760-A | Lyophilized thioxanthenone antitumor agents | SANOFI WINTHROP, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997010809-A1 | LYOPHILIZED THIOXANTHENONE ANTIMUMOR AGENTS | SANOFI (FR) | 1997-03-27 | — | — | WO | disclosed |
| US-5380749-A | Thioxanthenone antitumor agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0619315-A1 | Thioxanthenone antitumor agents | STERLING WINTHROP INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| US-5346917-A | For mammals | STERLING WINTHROP INC. (US) | 1994-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | MAPT, TTR, HTT | MEN1 2502/4885GAA 215/4885MAPT 1/4885 |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | MEN1 4355/4885GAA 1059/4885MAPT 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.